MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Principal trial goals had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, although one of many exploratory https://horacer998epz1.blogofchange.com/profile